PURPOSE: Hypoxia has been found to play an important role in regulating the biological characteristics of cancer stem cells (cCSCs). In this study, we tested whether a tumor hypoxic niche serves to the chemotherapeutic resistance of colon cCSCs. METHODS: Each of 23 fresh samples of human colon adenocarcinoma was transplanted into nude mice. The tumor-bearing mice randomly and equally received (A) saline, (B) 5-fluorouracil (15 mg/kg), (C) oxaliplatin (10 mg/kg), and (D) oxaliplatin plus 5-fluorouracil when xenografts reached 250 mm(3) (n = 10). After 2-week treatment, tumor cells were quantified by flow cytometry for expression of CD133 and the hypoxic proportion of CD133(+) and CD133(-) cells which were also sorted and detected for ki67 and pimonidazole via immunofluorescence. RESULTS: The hypoxic subpopulation of CD133(+) and CD133(-) cells was 66.5 and 26.4 %, respectively. Although there was no marked change for the hypoxic subpopulation of CD133(+) cells after treatment, the hypoxic fraction of proliferative CD133(+) cells was increased by 14.62, 16.45, and 20.46 % in groups B, C, and D, respectively. Furthermore, proliferative cells in CD133(+) and CD133(-) cells were reduced by 29.93 and 62.5 % in group C, and by 25.26 and 68.22 % in group D; in group B, however, the proliferative CD133(+) cells were increased by 37.09 %; the CD133(-) cells were unchanged. CONCLUSIONS: Most CD133(+) cCSCs are located in a hypoxic niche, where cCSCs are better at retaining proliferating property under chemotherapy. Oxaliplatin, rather than 5-FU, inhibits proliferation of cCSCs, which may be the mechanism underlying a better outcome by oxaliplatin in colon cancer patients.
PURPOSE:Hypoxia has been found to play an important role in regulating the biological characteristics of cancer stem cells (cCSCs). In this study, we tested whether a tumor hypoxic niche serves to the chemotherapeutic resistance of colon cCSCs. METHODS: Each of 23 fresh samples of humancolon adenocarcinoma was transplanted into nude mice. The tumor-bearing mice randomly and equally received (A) saline, (B) 5-fluorouracil (15 mg/kg), (C) oxaliplatin (10 mg/kg), and (D) oxaliplatin plus 5-fluorouracil when xenografts reached 250 mm(3) (n = 10). After 2-week treatment, tumor cells were quantified by flow cytometry for expression of CD133 and the hypoxic proportion of CD133(+) and CD133(-) cells which were also sorted and detected for ki67 and pimonidazole via immunofluorescence. RESULTS: The hypoxic subpopulation of CD133(+) and CD133(-) cells was 66.5 and 26.4 %, respectively. Although there was no marked change for the hypoxic subpopulation of CD133(+) cells after treatment, the hypoxic fraction of proliferative CD133(+) cells was increased by 14.62, 16.45, and 20.46 % in groups B, C, and D, respectively. Furthermore, proliferative cells in CD133(+) and CD133(-) cells were reduced by 29.93 and 62.5 % in group C, and by 25.26 and 68.22 % in group D; in group B, however, the proliferative CD133(+) cells were increased by 37.09 %; the CD133(-) cells were unchanged. CONCLUSIONS: Most CD133(+) cCSCs are located in a hypoxic niche, where cCSCs are better at retaining proliferating property under chemotherapy. Oxaliplatin, rather than 5-FU, inhibits proliferation of cCSCs, which may be the mechanism underlying a better outcome by oxaliplatin in colon cancerpatients.
Authors: Maria V Gustafsson; Xiaowei Zheng; Teresa Pereira; Katarina Gradin; Shaobo Jin; Johan Lundkvist; Jorge L Ruas; Lorenz Poellinger; Urban Lendahl; Maria Bondesson Journal: Dev Cell Date: 2005-11 Impact factor: 12.270
Authors: Laurence Goethals; Annelies Debucquoy; Christiaan Perneel; Karel Geboes; Nadine Ectors; Harlinde De Schutter; Freddy Penninckx; William H McBride; Adrian C Begg; Karin M Haustermans Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-01 Impact factor: 7.038
Authors: Nadine Platet; Shi Yong Liu; Michèle El Atifi; Lisa Oliver; François M Vallette; François Berger; Didier Wion Journal: Cancer Lett Date: 2007-10-30 Impact factor: 8.679
Authors: John Dosch; Elise Hadley; Cal Wiese; Marissa Soderberg; Tori Houwman; Kai Ding; Alexandra Kharazova; John L Collins; Bart van Knippenberg; Carl Gregory; Alexander Kofman Journal: Cell Cycle Date: 2017-12-26 Impact factor: 4.534
Authors: Min Pan; Michael A Reid; Xazmin H Lowman; Rajan P Kulkarni; Thai Q Tran; Xiaojing Liu; Ying Yang; Jenny E Hernandez-Davies; Kimberly K Rosales; Haiqing Li; Willy Hugo; Chunying Song; Xiangdong Xu; Dustin E Schones; David K Ann; Viviana Gradinaru; Roger S Lo; Jason W Locasale; Mei Kong Journal: Nat Cell Biol Date: 2016-09-12 Impact factor: 28.824